Round II for D.C. price controls

PhRMA and BIO filed a joint brief last week in a lawsuit that could fundamentally alter the balance of power between pharmaceutical manufacturers and state governments. The stakes are high: an industry victory could create disincentives for states to imitate the District of Columbia's effort to impose price controls on drugs, while a partial victory for the city would encourage local governments to keep trying.

The joint filing in the U.S. Court of Appeals for the Federal Circuit (CAFC) is the latest round in the trade associations' battle against a Washington,

Read the full 902 word article

How to gain access

Continue reading with a
two-week free trial.